– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.

– Hochuen Medical from Shenzhen is developing and producing microfluidic and IVD devices for more than 200 companies.
– The company raised RMB 40M in Series A funding.
– The round was led by Qiming Venture Partners.
– The new investment will be used to accelerate the company’s contract development and manufacturing organization, expand in both international and domestic markets, develop new manufacturing processes and technologies, and further expand production capacity.

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

– WeRide, a Chinese autonomous driving company, raised “hundreds of millions” in Series C funding.
– The round was led by IDG Capital, Homeric Capital, CoStone Capital, Cypress Star, Sky9 Capital and K3 Ventures, and existing investors CMC Capital Partners, Qiming Venture Partners and Alpview Capital.
– The company intends to use this funding round to invest in R&D and commercialization as it works toward the next-generation of Level 4 driving, a term that means a vehicle can drive without human intervention in some environments and conditions.
– The company is also using the funds to prepare to commercialize its technology.

– imToken, a world-class blockchain technology company best known for its secure decentralized digital wallet, today announced the completion of a US$30 million Series B financing led by Qiming Venture Partners, with participation from its lead Series A investor IDG Capital and new investors including Breyer Capital, HashKey, Signum Capital, Longling Capital, SNZ and co-founder of Fosun International, Mr. LIANG Xinjun.
– imToken was founded in 2016 to address a lack of user-friendly entry points to the cryptocurrency space. In line with its belief that digital asset wallets are the most secure and cost-effective way of banking, the company set out to make the world of decentralized digital wallets more easily and securely accessible by creating a wallet platform with unprecedented ease-of-use and industry leading platform security.

– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.